Arrowhead Pharmaceuticals, Inc.
NEWS
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week’s appointments.
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
Two pharmaceutical companies and a medtech maker snagged three of the top-10 spots on Deloitte’s 2018 North America Technology Fast 500, a ranking of the fastest-growing North American companies in the fields of technology, life sciences, telecommunications, media and energy.
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals’ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops.
JOBS
IN THE PRESS